Compare · ADN vs TMO
ADN vs TMO
Side-by-side comparison of Advent Technologies Holdings Inc. (ADN) and Thermo Fisher Scientific Inc (TMO): market cap, price performance, sector, and recent activity on the wire.
Summary
- ADN operates in Miscellaneous, while TMO operates in Industrials - the two are in different parts of the market.
- TMO is the larger of the two at $174.52B, about 2134.8x ADN ($81.8M).
- Over the past year, ADN is down 67.5% and TMO is up 14.9% - TMO leads by 82.4 points.
- TMO has hit the wire 17 times in the past 4 weeks while ADN has been quiet.
- TMO has more recent analyst coverage (25 ratings vs 0 for ADN).
- Company
- Advent Technologies Holdings Inc.
- Thermo Fisher Scientific Inc
- Price
- $0.91-66.30%
- $469.56-0.67%
- Market cap
- $81.8M
- $174.52B
- 1M return
- -72.84%
- -1.03%
- 1Y return
- -67.50%
- +14.92%
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- NASDAQ
- NYSE
- IPO
- 2018
- News (4w)
- 0
- 17
- Recent ratings
- 0
- 25
Advent Technologies Holdings Inc.
Advent Technologies Holdings, Inc., an advanced materials and technology development company, operates in the fuel cell and hydrogen technology markets. It develops, manufactures, and assembles the critical components that determine the performance of hydrogen fuel cells and other energy systems. The company offers HT-PEM (high-temperature proton exchange membrane) fuel cells, HT-PEM based membrane electrode assemblies, flow battery membranes, organic photovoltaics, and ultracells. It serves stationary power, portable power, automotive, aviation, energy storage, and sensor markets. The company was founded in 2006 and is headquartered in Boston, Massachusetts.
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Latest ADN
- SEC Form 25-NSE filed by Advent Technologies Holdings Inc.
- SEC Form 25-NSE filed by Advent Technologies Holdings Inc.
- Advent Technologies Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Leadership Update, Financial Statements and Exhibits
- SEC Form 10-Q filed by Advent Technologies Holdings Inc.
- SEC Form NT 10-Q filed by Advent Technologies Holdings Inc.
- Advent Technologies Holdings Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement
- SEC Form 8-K filed by Advent Technologies Holdings Inc.
- Advent Technologies Powers the Future of Flight with Next-Generation Fuel Cell Technology
- Advent Technologies Holdings Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- Advent Technologies Commissions Arxicon as Master Planner for RHyno Project
Latest TMO
- Thermo Fisher downgraded by HSBC Securities with a new price target
- Wolfe Research resumed coverage on Thermo Fisher with a new price target
- SEC Form SD filed by Thermo Fisher Scientific Inc
- Thermo Fisher Scientific Unveils Next-generation Innovations at ASMS 2026 to Accelerate the Path from Drug Discovery to New Therapies
- Thermo Fisher Scientific Inc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Director Weisler Dion J covered exercise/tax liability with 80 shares and was granted 499 shares, increasing direct ownership by 8% to 5,446 units (SEC Form 4)
- Director Sperling Scott M was granted 499 shares, increasing direct ownership by 0.72% to 69,479 units (SEC Form 4)
- Director Spar Debora L was granted 499 shares, increasing direct ownership by 24% to 2,610 units (SEC Form 4)
- Director Lynch Karen S was granted 499 shares, increasing direct ownership by 76% to 1,159 units (SEC Form 4)
- Director Keith R. Alexandra was granted 499 shares, increasing direct ownership by 24% to 2,602 units (SEC Form 4)